Bluejay Diagnostics Q1 2026: net loss $1.9M, SYMON-II study at 680 of 750 patients

Bluejay Diagnostics, Inc.

Cash and equivalents $3.7M as of Mar 31, 2026; net loss $1.9M unchanged YoY.
SYMON-II pivotal study enrollment at ~680 patients toward target of 750.
Resolved manufacturing issues with Sanyoseiko; progressing toward analytical/clinical validation.
Continuing FDA 510(k) strategy for Symphony IL-6 test after validation activities.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Bluejay Diagnostics, Inc. reported fiscal quarter ended March 31, 2026 results: net income approximately $1.9 million.

Period: fiscal quarter ended March 31, 2026
Net income: approximately $1.9 million
Result: reported results

Exact text from the filing

As of March 31, 2026, Bluejay reported cash and cash equivalents of approximately $3.7 million. The Company reported a net loss of approximately $1.9 million for the first quarter of 2026, compared to approximately $1.9 million for the same period in 2025.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Bluejay Diagnostics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-053295

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.